5'-Nucleotidase
5'-nucleotidase (5NT) is an important liver enzyme used for the differential diagnosis of cholestasis/biliary obstruction. Specifically, the purpose of the enzyme is to hydrolyze phosphate from 5'-adenosine monophosphate (AMP). Information from the 5NT level is used to differentiate osteoblast alkaline phosphatase from hepatocellular alkaline phosphatase, because diseases of the bone do not increase 5NT. Differentiation of bone versus liver ALP is necessary in children, who will usually have an elevated ALP.
Increased levels of 5NT usually follow increased levels of alkaline phosphatase and leucine aminopeptidase in hepatobiliary and other obstructive liver diseases. Although it parallels the levels of alkaline phosphatase in many liver diseases, it will not follow elevated levels of alkaline phosphatase in skeletal disorders such as Paget’s disease of bone, making this more specific for liver diseases. 5NT is also increased in metastatic neoplasia to the liver, in primary biliary cirrhosis, biliary obstruction from calculi, and liver tumors. The Gamma-glutamyl transpeptidase (GGT) test is much more sensitive in hepatic metastases, but 5NT is a confirmatory measurement. In patients with infectious hepatitis, GGT and 5NT will usually rise and fall at the same time. A secondary rise indicates exacerbation. In these cases, both tests are equally sensitive and will provide the same information.
- This test is used mainly in the differential of liver and biliary diseases, especially those with cholestasis, either intrahepatic or extrahepatic. It correlates with the level of liver Alkaline Phosphatase and is not affected by bone diseases. Levels are increased in infants and the elderly.
- Differential diagnosis of diseases involving the liver
- Differential diagnosis of cholestasis/biliary obstruction
- Management of patients with infectious hepatitis
- Diagnosis of hepatic metastases
- Differentiating elevated bone alkaline phosphate levels from elevated liver alkaline phosphatase levels
Increased in:
- Cholestasis
- Biliary cirrhosis, early
- Biliary obstruction, either intra- or extrahepatic
- Destruction of liver cells
- Hepatitis
- Liver ischemia
- Liver tumor
- Pregnancy, third trimester
- Preeclampsia
- Graft verus Host disease
- Metastatic neoplasia to the liver
- Use of a liver-damaging drug
- Infants
- Certain drugs will artifactually increase serum values including: Acetominaphen, Phenytoin and some other anticonvulsants, Aspirin, Asparaginase, Drugs known to cause cholestasis and Carbenoxolone.
- Interfering substances during testing include hemolysis, Magnesium, Nickel and EDTA.
- May be increased in bone metastasis (very low levels)
5NT is used in the differential diagnosis of liver disease and porta hepatis obstruction. Normal to minimally increased levels are seen in liver disease, such as those of hepatitis and liver infections, as well as skeletal diseases. Markedly increased (>5 times) levels are found in hepatobiliary obstruction-related diseases, such as those of biliary cirrhosis or intrahepatic cholestasis.
2-17 U/L (0.03-0.29 µKat/L)
Serum (SST).
Stability
- Ambient: 24 hours
- Refrigerated: 7 days
- Frozen: 14 days
ALT, AST, Total and direct bilirubin, Hepatitis profile (including hepatitis virus A, B and C serology), Gamma-Glutamyl Transferase (GGT), Liver biopsy, Alkaline phosphatase with isoenzymes.
- Clin Chim Acta. 1972 Mar;37:525-9. [PMID: 5022117]
- Dig Dis Sci. 1988 Dec;33(12):1601-14. [PMID: 2904353]
- Obstet Gynecol. 1988 Aug;72(2):171-4. [PMID: 2839808]
- Dig Dis Sci. 1988 Dec;33(12):1601-14. [PMID: 2904353]
- Kaplan A. Clinical Chemistry: Interpretation and Techniques. Malvern, PA: Lippincott Williams & Wilkins (1995).
- Alan Wu. Tietz Clinical Guide to Laboratory Tests, Fourth Edition. Saunders; 4 edition (June 13, 2006). ISBN-10: 0721679757.